Analysis of Midterm Readmissions and Related Costs after Open and Endovascular Procedures for Aorto-Iliac Occlusive Disease
- PMID: 39063553
- PMCID: PMC11278191
- DOI: 10.3390/life14070798
Analysis of Midterm Readmissions and Related Costs after Open and Endovascular Procedures for Aorto-Iliac Occlusive Disease
Abstract
Background. Readmissions rates and costs were analysed over follow-up for patients who underwent open or endovascular procedures for aorto-iliac occlusive disease (AIOD). Methods. Patients who underwent aorto-bifemoral bypass (ABF) or covered kissing stent (CKS) for AIOD from May 2008 to February 2018 were compared in terms of readmission rates, related costs expressed in EUR, freedom from generic readmission (FFGR), and freedom from readmission for surgical reasons (FFRS). Results. ABF had a readmission rate of 16% and CKS of 18% (p = 0.999). The most common cause of readmission was prosthesis limb or stent occlusion. Time to readmission was longer for ABF (35 months [21-82] vs. 13.5 months [1-68.7] in the CKS group, p = 0.334). CKS group had higher cumulative re-hospitalisation, ICU stay, and reintervention costs (11569 ± 2216 SEM, 2405 ± 1125, 5264 ± 1230, respectively) and a trend for more readmissions in the first 36 months, without reaching significance. Conclusion. This study reports on a period of time exceeding ninety days. Even if not reaching significance, the CKS group presented a higher trend in readmissions till 36 months and a higher trend in readmission costs, while time-to-readmission was longer in the ABF group.
Keywords: aorto-iliac occlusive disease; cost-analysis; in-hospital readmissions.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Comparison of Direct and Less Invasive Techniques for the Treatment of Severe Aorto-Iliac Occlusive Disease.Ann Vasc Surg. 2018 Jan;46:226-233. doi: 10.1016/j.avsg.2017.07.002. Epub 2017 Jul 21. Ann Vasc Surg. 2018. PMID: 28739459 Free PMC article.
-
Open Versus Endovascular Repair With Covered Stents for Complex Aortoiliac Occlusive Disease: Cost Analysis Results.Ann Vasc Surg. 2023 Nov;97:382-391. doi: 10.1016/j.avsg.2023.05.029. Epub 2023 Jun 1. Ann Vasc Surg. 2023. PMID: 37268106
-
Propensity-Matched Comparison of Endovascular versus Open Reconstruction for TASC-II C/D AortoIliac Occlusive Disease. A Ten-Year Single-Center Experience with Self-Expanding Covered Stents.Ann Vasc Surg. 2021 Feb;71:84-95. doi: 10.1016/j.avsg.2020.08.139. Epub 2020 Sep 11. Ann Vasc Surg. 2021. PMID: 32927036
-
Endovascular Aorto-Iliac Reconstruction vs. Aortobifemoral Bypass as First Choice for a Durable Revascularization for Aorto-Iliac Occlusive Disease.Vasc Endovascular Surg. 2023 Jan;57(1):88-92. doi: 10.1177/15385744221130870. Epub 2022 Sep 29. Vasc Endovascular Surg. 2023. PMID: 36172836 Review.
-
Meta-analysis of direct surgical versus endovascular revascularization for aortoiliac occlusive disease.J Vasc Surg. 2020 Aug;72(2):726-737. doi: 10.1016/j.jvs.2019.12.035. Epub 2020 Mar 11. J Vasc Surg. 2020. PMID: 32171442
References
-
- Davenport D.L., Zwischenberger B.A., Xenos E.S. Analysis of 30-day readmission after aortoiliac and infrainguinal revascularization using the American College of Surgeons National Surgical Quality Improvement Program data set. J. Vasc. Surg. 2014;60:1266–1274. doi: 10.1016/j.jvs.2014.05.051. - DOI - PubMed
-
- Management of peripheral arterial disease (PAD) TransAtlantic Inter-Society Consensus (TASC) Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. 2000;19:S1–S250. - PubMed
LinkOut - more resources
Full Text Sources